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Low dietary intakes of the n-3 long-chain PUFA (LCPUFA) EPA and DHA are thought to be associated with increased risk for a variety of adverse
outcomes, including some psychiatric disorders. Evidence from observational and intervention studies for a role of n-3 LCPUFA in depression is
mixed, with some support for a benefit of EPA and/or DHA in major depressive illness. The present study was a double-blind randomised con-
trolled trial that evaluated the effects of EPA þ DHA supplementation (1·5 g/d) on mood and cognitive function in mild to moderately depressed
individuals. Of 218 participants who entered the trial, 190 completed the planned 12 weeks intervention. Compliance, confirmed by plasma fatty
acid concentrations, was good, but there was no evidence of a difference between supplemented and placebo groups in the primary outcome –
namely, the depression subscale of the Depression Anxiety and Stress Scales at 12 weeks. Mean depression score was 8·4 for the
EPA þ DHA group and 9·6 for the placebo group, with an adjusted difference of 21·0 (95% CI 22·8, 0·8; P¼0·27). Other measures of
mood, mental health and cognitive function, including Beck Depression Inventory score and attentional bias toward threat words, were similarly
little affected by the intervention. In conclusion, substantially increasing EPA þ DHA intake for 3 months was found not to have beneficial or
harmful effects on mood in mild to moderate depression. Adding the present result to a meta-analysis of previous relevant randomised controlled
trial results confirmed an overall negligible benefit of n-3 LCPUFA supplementation for depressed mood.
Depressed mood: Cognitive function: EPA: DHA
It is thought that in many countries current population intakes
of the n-3 long-chain PUFA (LCPUFA; also known as long
chain omega-3 fatty acids) EPA and DHA are lower than opti-
mal for a variety of health outcomes1,2. In modern Western
diets the principal source of these fatty acids is fish, particu-
larly oily fish, which are relatively unpopular foods. Coupled
with this there has been a rise in recent decades in intakes of
oils and foods rich in n-6 LCPUFAs1. A decrease in the ratio
of n-3 LCPUFA:n-6 LCPUFA intake in the diet has, in turn,
been implicated in the aetiology of psychiatric disorders,
including depression3–6, which itself is a major and increasing
contributor to the global disease burden7.
DHA is a component of cell membrane phospholipids
and its concentration can affect membrane fluidity and
activity of membrane receptors and ion channels1,4. EPA
is a precursor of DHA and of a variety of eicosanoid
immune-neuroendocrine regulatory compounds, including
PG, thromboxanes, prostacyclins and leukotrienes1,4.
Animal studies have found effects of dietary concentrations
of n-3 LCPUFA on phospholipid fatty acid composition and
monoaminergic neurotransmission8,9.
In relation to depression, clinical studies have revealed associ-
ations between blood measures of fatty acid status and severity
of depression10 and differences in fatty acid status between
people with depression and age-matched controls11–13, in the
direction of a lower n-3 LCPUFA concentration and lower n-3
LCPUFA:n-6 LCPUFA ratio in depression. Another study
found an inverse relationship between adipose tissue DHA con-
centration and mild depression in a non-clinical sample14.
Associations have also been noted between low dietary intakes
of n-3 LCPUFA or fish and prevalence of depression across
time and between and within countries3,15–17. On the other
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hand, we found only a weak non-linear association between
depressed mood and n-3 LCPUFA intake from fish, which
appeared to be confounded by age and level of social and econ-
omic deprivation18. Hakkarainen et al.19 similarly reported no
association between intakes of n-3 LCPUFA or fish and
depressed mood and also no association with major depressive
episodes or suicide. Another study found elevated levels of n-3
LCPUFA in patients with depression20.
Evidence from intervention studies investigating the
effects of increasing n-3 LCPUFA intakes on depression is
also mixed. A recent review of this evidence identified
eighteen relevant randomised controlled trials, of which
twelve met the criteria for inclusion in meta-analysis21.
The evidence overall amounted to limited benefit of n-3
LCPUFA for depressed mood, although a beneficial effect
was found in trials that enrolled clinical populations diag-
nosed with depressive illness. These latter trials, however,
tended to be small (n 20–77) and the doses of n-3
LCPUFA (up to 9·6 g/d) associated with the largest effects
in adults were very much higher than could be realistically
achieved through diet.
The purpose of the present trial was to examine the
effects of raising intakes of EPA and DHA on depressed
mood in mild to moderately depressed individuals from
the general population who were not receiving conventional
treatments for depression. The participants were individuals
who displayed evidence of depressed mood, but whose
symptoms did not meet criteria for major depression.
Anxiety, stress and anger were included as secondary out-
comes due to their co-morbidity with depression22,23. Simi-
larly, performance on various cognitive tasks was assessed
because depressed mood is associated with impaired cogni-
tive function24 and, independent of effects on mood, there
is interest in possible benefits of n-3 LCPUFA supplemen-
tation for cognition5,25,26. The amounts of n-3 LCPUFA
(EPA þ DHA) provided in the supplement were substan-
tially in excess of current UK dietary targets2, but poten-
tially achievable through increased intake of oily fish and
certainly so through the use of widely available fish oil
supplements.
In summary, while a majority of previous trials have
focused on individuals with severe depression in clinical set-
tings and have mostly administered high amounts of n-3
LCPUFA, the present trial was concerned with investigating
possible benefits in mild to moderate depression of an intake
of n-3 LCPUFA that many in the general population might
attain by appropriate changes in diet, supplement use or
both. The prevalence of mild to moderate depression is
substantial27 and many people with mild to moderate
depressive symptoms present in primary care, where there
is concern about rising levels of prescribing conventional
antidepressant treatments. Interest in finding safe alternative
treatments with proven efficacy is therefore high. Appropri-
ately, the main route of recruitment for the trial was through
primary care settings; however, above all, the trial was
designed to be relevant to the general population
rather than the treatment of clinical (i.e. major) depression.
It was hypothesised that supplementation with EPA þ
DHA for 12 weeks would improve mood and cognitive
function.
Methods and materials
Trial design and participants
This was a single centre, double-blind randomised controlled
trial that evaluated EPA þ DHA supplementation v. placebo
in 218 mildly moderate depressed individuals, of whom 190
completed the planned 12 weeks of supplementation.
A flow diagram summarising progress through the trial is
presented in Fig. 1. Participants were recruited into the trial fol-
lowing two screens completed 2–4 weeks apart (screens 1
and 2). Screening questionnaires assessed demographics,
EPA þ DHA intake and depressed mood. EPA þ DHA intake
was assessed using a short dietary questionnaire, the PolyUnsa-
turated Fatty Acids Questionnaire (PUFAQ), developed specifi-
cally for the trial. It enquired about the recent (previous 3
months) frequency of intake of various sources of dietary fat,
including white fish and oily fish, and intake of dietary sup-
plements including fish oils. Responses were coded such that a
score of 1 represented an EPA þ DHA intake equivalent to con-
suming one portion of oily fish perweek (based on data frompre-
vious studies2). Depressed mood was assessed using the short
form of the Depression, Anxiety and Stress Scales (DASS)28.
Two screens were undertaken to exclude those with transient
disturbance of mood. Participants were suitable for the trial if
at screens 1 and 2 they were no more than moderate consumers
of EPA and DHA (PUFAQ score of#1·5); suffering from mild
to severe depressed mood (DASS depression score 10–24;
scores of 21–27 are classified as ‘severe’ and $ 28 as ‘extre-
mely severe’), aged 18-70 years old, not pregnant or breast feed-
ing, not severely ill, not taking antidepressant medication for
depression, not known to suffer frommedical or other conditions
that contraindicated use of the active or placebo supplement (e.g.
gastrointestinal conditions, food intolerances, food allergies,
special diets), fluent English speakers (because both the ques-
tionnaire and cognitive functionmeasures were critically depen-
dent on a good understanding of English).
Most of the participants were recruited via general practice
surgeries in Bristol (Table 1). Researcher-based recruitment
took place from May to September 2003 in thirteen general
practice surgeries. For a randomly selected 2-week period
during this time, screening questionnaires were handed out by
researchers to all persons in the waiting room between 08.30
and 11.00 hours. Potential participants completed the screening
questionnaires and their willingness to take part in the trial was
noted. Questionnaire box-based recruitment, for which posters
highlighting the trial and recruitment questionnaires were
placed in waiting rooms in forty-seven general practice sur-
geries, took place from September 2003 to December 2004.
If desired, completed questionnaires could be returned by free-
post to the research unit rather than being placed in the collec-
tion box. Further participants were recruited at two events,
Science Week in a Bristol city centre shopping mall (March
2004) and Freshers’ Fair at the University of Bristol (Septem-
ber 2004), and through advertising in the local media (newspa-
pers and radio, January 2004) and around the University of
Bristol (January, April and October 2004). These various
methods of recruitment were undertaken to maximise partici-
pation of individuals with low mood who had not been labelled
as depressed in a clinical setting. This recruitment strategy also
helped to improve the generalisability of the trial.
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Fig. 1. Flow diagram of progress through the trial. LCPUFA, long-chain PUFA; PUFAQ, PolyUnsaturated Fatty Acids Questionnaire; DASS, Depression, Anxiety
and Stress Scale; DASS-d, DASS depression; BDI, Beck Depression Inventory; STAXI, State-Traint Anger Expression Inventory; GHQ, General Health Question-
naire. For details of subjects and procedures, see Methods and materials.
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Informed consent was obtained from all participants prior to
their inclusion in the trial. Approval for the trial was granted
by Southmead Local Research Ethics Committee, United
Bristol Healthcare Trust Research Ethics Committee,
Frenchay Research Ethics Committee and NHS Primary
Care Trusts for Bristol North and Bristol South and West.
Intervention
Participants were instructed to consume three capsules daily.
These three capsules contained a total of either 630mg EPA,
850mg DHA, 870mg olive oil, 7·5mg mixed tocopherols and
12mg orange oil (EPA þ DHA, the active treatment) or
2360mg olive oil, 7·5mg mixed tocopherols and 12mg orange
oil (placebo treatment). The capsule casing was made from
fish gelatine. Active and placebo capsules were identical in
appearance. The orange oil was included to improve palatability
and blinding. If bitten into, their predominant flavourwas orange
with an oily aftertaste. These capsules were purchased from
Minami Nutrition SA (Antwerp, Belgium), who prepared them
especially for the trial. They were supplied to participants in
sealed, child-safe, plastic containers labelled with the partici-
pant’s identification number.
Outcome measures
The primary outcome was depressed mood at 12 weeks
follow-up, measured by the depression subscale of the
DASS (long form)28. Secondary outcome measures were the
Beck Depression Inventory (BDI)29, which is commonly
used in clinical trials of treatments for depression, the anxiety
and stress subscales of the DASS, the General Health Ques-
tionnaire30, the state anger subscale of the State-Trait Anger
Expression Inventory31, mood assessed using a diary and a
visual probe task, and cognitive function assessed using var-
ious tasks. The DASS is suitable for the assessment of
depression in general population samples and correlates
fairly highly with the BDI (r 0·74), the difference in perform-
ance between these instruments being due largely to the
inclusion of items in the BDI that assess somatic symptoms
that do not appear to be strongly or uniquely related to
depression28.
For the mood diary, participants recorded their mood on ten
clusters of descriptors (e.g. happy/cheerful/light-hearted,
drowsy/sluggish/fatigued, clear-headed) rated on 100mm uni-
polar line scales anchored at either end with ‘not at all’ and
‘extremely’. Ratings were made at six pre-specified times
(08.00, 11.00, 13.00, 16.00, 18.00 and 21.00 hours) daily for
3 d. A similar method was previously used successfully in a
study of the effects of cholesterol-lowering on mood32. The
visual probe task was based on methods described by MacLeod
& Mathews33 and Mogg & Bradley34. It formed part of the
battery of computer-presented cognitive tasks detailed later.
Each trial of the visual probe task began with the appearance
of a central fixation cross, which was replaced by two words,
one appearing on the left and one on the right of the computer
screen for 500ms. Next, immediately after the words disap-
peared, a left or right pointing arrow (the probe) appeared on
the left or right of the screen and the participant had to indicate
as quickly as possible with a key press the direction of the arrow.
One of the words presented was physically or socially threaten-
ing in nature (e.g. coffin, pathetic) and one was neutral, matched
for initial letter, word length, number of syllables and, as far as
possible, frequency of general use, with the threatening word
(e.g. collar, portable). The advantage of implicit (reaction
time) measures of this type is that they are free from potential
biases, such as impression management and social desirability,
which can undermine the validity of mood questionnaires and
interview methods.
Other aspects of cognitive function, including speed of
information processing, reasoning using lexical and numerical
cues, impulsivity and working memory were assessed using
the following tasks: simple reaction time35; lexical decision36;
digit–symbol substitution37; impulsivity35; N-Back38. Pre-
vious studies have found differences in performance between
depressed and non-depressed individuals on all these
tasks24,34,36,39,40 and some have reported improvement in per-
formance alongside improvement in depressed mood during
treatment for depression36,40. All cognitive tasks were pro-
grammed and presented using E-Prime 1·0 (Psychology Soft-
ware Tools Inc., Pittsburgh, PA, USA) run on networked PC
with 15-inch colour monitors and standard keyboards. They
were undertaken in the afore-mentioned order, with the
visual probe task occurring second to last, as a single battery
lasting 45min and were preceded on every occasion by a prac-
tice battery lasting 5–10min, which contained all the tasks in
shortened form. The purpose of this practice was to familiarise
and re-familiarise participants with the tasks.
Compliance with the trial protocol was assessed using
self-reported number of days on which capsules were taken,
a count of the number of capsules returned and plasma fatty
acid composition measured from fasting venous blood samples
collected from all participants willing to provide blood. Anal-
ysis of fatty acid composition was carried out using GC.
Total lipid was extracted from plasma with 2:1 (vol./vol.)
Table 1. Number of participants recruited into the trial using each method of recruitment†
Researcher-based recruitment* Questionnaire box-based recruitment* Other methods Total
Number of people available 5167 Unknown Unknown Unknown
Number who completed questionnaires 2982 2050 448 5480
Number of volunteers 1786 2050 448 4284
Number of volunteers suitable (screen 1) 387 557 118 1062
Number of volunteers suitable (screen 2) 89 218 57 364
Number recruited into the trial 28 145 45 218
* Via general practice surgeries.
† For details of subjects and procedures, see Methods and materials.
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chloroform and methanol. Fatty acid methyl esters were pre-
pared by incubation of lipid with methanol containing 2%
(v/v) sulphuric acid at 508C for 2 h. Fatty acid methyl esters
were separated using a Hewlett Packard 6890 gas chromato-
graph (Agilent Technologies UK Ltd, Wokingham, Berks.,
UK) equipped with a 30 m £ 0·25 mm £ 0·25mm BPX-
70 fused silica capillary column (SGE, Milton Keynes, UK)
and flame ionisation detection. The concentrations of individ-
ual fatty acids were determined by measurement of the peak
area using ChemStation software (Agilent) and each fatty
acid was expressed as a proportion of the total (see Burdge
et al.41 for further details).
Measurements were taken at baseline (week 0) and weeks 4
and 12 of supplementation. At each time point, participants
were required to attend the Psychology Research Unit, Univer-
sity of Bristol starting at either 08.00 or 10.00 hours for 2 h. A
few days before, participants were sent the questionnaires,
which were completed at home. These were returned and
checked during their visit. On arrival, participants were first
required to provide a blood sample and were weighed and
their height measured. Participants were then given 30min
to consume breakfast. On their first visit, participants were
free to consume whatever they chose for breakfast, but
were requested to eat their usual breakfast if possible,
and were asked to record this. On weeks 4 and 12, participants
were asked to have this same breakfast to control for possible
effects of breakfast on cognitive performance. Following the
test batteries, participants were provided with their capsules
and instructions on how to take them. Finally, participants
were provided with a mood diary, to be completed over the
following 3 d and returned by post. Participants were free to
ask questions throughout the visit and were encouraged to
telephone the researchers from home if necessary. Participants
were contacted by telephone prior to each visit to confirm their
appointment.
Sample size
A difference in means of between 3 and 4 points on the DASS
depression scale (maximum range 42) was considered thera-
peutically meaningful, as such a decrease would be likely to
result in the level of depression falling by one category (e.g.
moderate to mild)28. Using a standard deviation in DASS
depression score of 7 points, for a power of 85% and a
two-tailed significance level of 5%, 200 participants would
be needed to detect a difference in means of 3 DASS
depression score points. For a difference of 4 points, power
would be 98%. To allow for attrition of 15–20%, it was
initially intended that 240 participants would be recruited.
Randomisation and blinding
Randomisation was stratified by gender, age (,50 and $50
years) and DASS depression score at screen 2 (10–16 and
17–24), with computer-generated random allocations con-
ducted using (randomly selected) blocks of six or eight. The
supplier provided the capsules in sealed plastic containers
(with the two groups distinguishable but blinded) and unique
trial identification numbers were then attached by researchers
not involved in participant recruitment or testing (T.J.P., D.G.)
according to the allocation schedule. Randomisation of
participants entering the trial was achieved through consecu-
tive allocation of an identification number to each individual
within each stratum by a trial researcher (K.M.A.). On pro-
vision of completed consent forms and baseline measures,
the allocated container was unsealed and three capsules were
removed to allow verification of treatment group at a later
date if necessary.
The trial was presented to participants as a study of the
effects of ‘dietary supplements on health and well-being’
and they were told that the capsules contained components
of a natural healthy diet (e.g. vitamins and oils). Fish and
fish oils were not mentioned explicitly in this context. Success
of these blinding procedures was evaluated during debriefing
by asking participants to identify whether they had received
‘active’ or ‘placebo’ supplements and then asking them what
they thought the supplements had contained.
Statistical methods
Data analyses were performed using SPSS 12.0.1 (SPSS Inc.,
Chicago, IL, USA) and Stata Release 9 (StataCorp LP,
College Station, TX, USA), commencing with descriptive stat-
istics to describe and investigate comparability of the two ran-
domised groups. The primary comparative analysis of the
intervention was conducted on an intention-to-treat basis,
employing regression to compare the outcomes between the
groups at week 12 adjusting for baseline score for the outcome
variable, age and gender. The method of last observation car-
ried forward was used to replace the small number of missing
values. Secondary analyses involved per-protocol regression
models and interaction tests to compare the effects of sup-
plementation across subgroups. These pre-specified subgroup
analyses were based on DASS depression score at baseline
(,14 v. $14, which is the boundary between mild and mod-
erate depression severity28).
The mood diary data were subjected to factor analysis
(using the method of principal factoring with varimax
rotation) to ascertain if there was a smaller number of under-
lying dimensions by which they could be characterised. Scores
on the resulting latent variables were then subjected to the
between-group comparisons described earlier using linear
regression models (except that, due to larger amounts of miss-
ing data, baseline values were not included in these analyses).
Results
Baseline characteristics and compliance
Baseline characteristics of the participants were similar across
the EPA þ DHA and placebo groups (Table 2; Figs. 2, 3).
Mean ages of the two groups were respectively 38·0 (SD 13·5)
and 38·2 (SD 13·7) years and eighty-five (78%) and eighty-
three (76%) were female. The mean DASS depression score
and age of the twenty-eight participants (thirteen in the
EPA þ DHA group and fifteen in the placebo group)
failing to complete their full course of supplements were 10·2
(SD 5·2) and 34·6 (SD 11·5) years, respectively, and twenty-
four (86%) were female. Reasons for non-completion of
supplementation were: not having sufficient time to devote to
the trial, given by six and seven participants (EPA þ DHA
and placebo respectively); the development of health problems
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Table 2. Depressed mood, cognitive function and other outcomes for EPA þ DHA and placebo groups at pre-supplementation baseline and after 4 and 12 weeks{
(Values are means and standard deviations)
Baseline Week 4 Week 12
Difference between
means at week 12*
(95 % CI)
EPA þ DHA Placebo EPA þ DHA Placebo EPA þ DHA Placebo
P
value†Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Intention-to-treat analysis (n 218)
DASS depression 10·9 6·1 11·0 5·5 8·5 7·3 9·8 6·5 8·4 8·0 9·6 7·3 21·02 (22·83, 0·81) 0·27
Beck Depression Inventory 13·9 6·3 13·9 7·2 11·1 6·9 11·2 6·6 10·6 7·6 9·9 6·5 0·63 (20·98, 2·24) 0·44
General Health
Questionnaire
65 23 64 23 55 24 57 23 55 27 54 26 0·5 (25·7, 6·6) 0·88
STAXI state anger 12·0 3·6 12·1 3·9 11·9 3·4 11·8 3·5 11·6 3·4 12·1 5·3 20·41 (21·49, 0·67) 0·46
DASS anxiety 6·0 5·7 6·0 5·1 4·8 4·3 5·2 4·9 4·3 4·8 5·1 5·4 20·73 (21·72, 0·25) 0·14
DASS stress 14·9 7·8 13·6 6·9 12·9 7·4 12·7 6·4 11·6 7·6 11·6 7·2 20·81 (22·36, 0·75) 0·31
Per protocol analysis (n 188)
DASS depression 11·1 6·1 11·0 5·8 8·5 7·6 9·7 6·5 8·5 8·4 9·4 7·5 21·09 (23·02, 1·09) 0·36
Intention-to-treat analysis (n 211–216)‡
Visual probe bias
score§ (ms)
23·9 23·9 25·3 28·5 1·5 25·7 21·8 28·3 20·5 25·6 22·3 28·8 1·5 (25·7, 8·8) 0·68
Simple reaction time (ms) 370 75 381 56 386 95 397 90 391 85 398 71 3 (210, 16) 0·64
Lexical decision (reaction
time; ms)
763 181 774 174 736 177 725 145 718 160 717 133 9 (218, 35) 0·52
Digit-symbol (reaction
time; ms)
1648 401 1774 463 1563 378 1643 386 1537 391 1608 418 19 (236, 75) 0·50
Impulsivity, number of errors 2·81 2·40 2·71 1·85 2·39 1·85 2·62 1·99 2·36 2·13 2·85 2·72 20·55 (21·14, 0·05) 0·07
N-back, number correct 13·1 5·9 11·9 5·4 12·5 6·5 11·6 6·3 12·1 6·9 11·0 6·5 0·4 (21·1, 1·9) 0·58
DASS, Depression, Anxiety and Stress Scales; STAXI, State-Trait Anger Expression Inventory.
* Mean difference between treatment groups (i.e. EPA þ DHA minus placebo) at week 12, adjusting for score at baseline and age and gender. Note that for all variables, lower scores signify better mood or cognitive function, except
for the N-back task where higher scores are better, and the visual probe task where zero scores indicate a lack of attentional bias.
† For difference at week 12.
‡ Numbers vary because at baseline accuracy was too low to calculate reaction times (emotional probe task), or because participants failed to complete a task, sometimes due to equipment breakdown.
§ Bias scores were calculated for individual participants as follows: median reaction time to the probe when it replaced neutral words minus median reaction time to the probe when it replaced threat words33.
{For details of subjects and procedures, see Methods and materials.
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unrelated to participation in the trial, given by two participants in
each group; the development of health problems related to
taking the capsules, given by two participants receiving
placebo (‘allergy’ to citrus flavouring, intolerance of high fat
content); one person became pregnant (placebo); one person
left the country (EPA þ DHA); four and three participants
were not contactable following their previous visit.
Mean DASS depression at screen 2 of the 218 participants
who subsequently entered the trial was 15·9 (SD 4·8) and their
mean PUFAQ score was 0·34 (SD 0·52). At baseline, depressed
mood had improved somewhat (Table 2); nevertheless, it
remained above the euthymic ranges on both the DASS
(scores of 10–13 are categorised as mild depression28) and
BDI (scores of 10–18 are categorised as mild to moderate
depression29). DASS depression at baseline was correlated
with BDI (r 0·62), General Health Questionnaire (r 0·66),
State-Trait Anger Expression Inventory, state anger (r 0·28),
DASS anxiety (r 0·45) and DASS stress (r 0·55) scores
(n 218, all P values ,0·01).
Results for compliance as measured by self-report (% of
days on which the capsules were consumed) and pill count
at week 12 were, respectively, 98 (SD3) % and 101 (SD11)
% in the EPA þ DHA group, and 98 (SD3) % and 102
(SD11) % in the placebo group. Results are above 100%
because pill counts indicated that some participants exceeded
the prescribed dose. There were similarly high levels of
compliance at week 4. From baseline to week 12, plasma
EPA þ DHA concentration doubled in the EPA þ DHA
supplemented group (P,0·00 001), but did not change in the
placebo group (P¼0·16) (Fig. 2).
There was no evidence of relationships between baseline
EPA and DHA concentrations, either alone or together, and
any of the mental health measures; in particular, plasma
EPA þ DHA concentration at baseline was not associated
with baseline DASS depression (n 185, linear regression coef-
ficient 20·11 (95% CI 20·97, 0·75; P¼0·80)).
Mood – primary and secondary outcomes
Mood and other aspects of mental health were not affected by
EPA þ DHA supplementation (Table 2). Specifically, the pri-
mary outcome of depressed mood improved over the 12 weeks
of the intervention, but to a similar extent in EPA þ DHA and
placebo groups. All the values in the 95% CI for the adjusted
difference in DASS depression score are smaller than those
specified as therapeutically significant in the a priori sample
size calculation.
Analyses based on data only from participants who fully
completed the trial also showed no effects of the intervention,
as did per protocol analyses that additionally omitted
two EPA þ DHA participants who had high plasma
EPA þ DHA concentrations at baseline due to fish oil sup-
plement use (which was not recognised until debriefing at
the end of the trial). Per protocol results for DASS depression
are shown in Table 2.
Regarding the subgroup analysis, while DASS depression
scores fell to a greater extent in the subgroup with higher
scores at baseline (Fig. 3), there was no evidence of a differ-
ential effect of EPH þ DHA across the two subgroups (week
12 supplementation by depression group interaction, P¼0·90).
Results were similar for the BDI, with participants in the
higher subgroup scoring on average at the top of the mild to
moderate depression BDI cut-off at baseline and remaining
within this range at week 12, but with no differential effect
of supplementation (P¼0·65).
The factor analysis performed on the mood diary data ident-
ified three components with eigenvalues .1, which corre-
sponded to ‘dysphoric mood’ (relaxed/calm (2 ), bad mood
(þ), happy/cheerful/light-hearted (2 ), tense/anxious/ner-
vous/on edge/stressed (þ), sad/gloomy/miserable (þ)),
‘drowsiness’ and ‘alertness and clear-headedness’. Not all
participants successfully completed their mood diaries. Analy-
sable data were available for seventy-seven EPA þ DHA and
seventy-four placebo participants at week 12. Drowsiness and
alertness and clear-headedness, but not dysphoric mood,
varied as a function of time of day (P , 0·001). All three
Fig. 3. Depression, Anxiety and Stress Scales (DASS) depression scores for
EPA þ DHA (X) and placebo groups (W) as a function of week of treatment
and level of depressed mood at baseline (week 0). Upper two lines, score at
baseline $14 (n 65); lower two lines, score at baseline ,14 (n 153). For
details of subjects and procedures, see Methods and materials.
Fig. 2. Plasma EPA ( ) and DHA (A) concentrations (% total fatty acids) in
EPA þ DHA treatment and placebo groups at baseline and after 4 and 12
weeks of supplementation (n 185, 149 and 150, respectively). Data are
means and error bars are standard errors of EPA þ DHA %. Between group
differences in mean (95 % CI) concentrations at week 12, adjusting for values
at baseline, age and gender, were: EPA, 1·53 (1·29, 1·77); DHA, 1·63 (1·41,
1·86); EPA þ DHA, 3·16 (2·74, 3·58); all P values ,0·00001. For details of
subjects and procedures, see Methods and materials.
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mood components were found to be unaffected by supplemen-
tation (P values . 0·1 for effects of supplementation and sup-
plementation by time of day interaction effects). Results for
dysphoric mood were as follows: EPA þ DHA 34·7 (SD
13·4); placebo 35·0 (SD 11·9); adjusted difference between
means 20·2 (95% CI 24·2, 3·8; P¼0·93).
Cognitive function
There was no evidence of effects of supplementation on cog-
nitive function (Table 2). Although there was a suggestion that
performance on the impulsivity task might be improved by
EPA þ DHA, the number of tests performed means that this
should be regarded with caution.
The negative emotional probe bias scores at baseline indi-
cate a propensity to avoid attending to threat words
(P¼0·012 from a t test for all 211 individuals combined).
This propensity was stronger in more depressed participants
(bias scores 211·9 (SD 22·2) and 21·5 (SD 27·3) ms for
DASS depression at baseline $14 and ,14, respectively;
difference between means adjusted for age and gender
210·4 (95% CI 22·7, 218·1; P¼0·009); however, sup-
plementation did not affect this measure in either subgroup
(all P levels .0·1).
Concealment of the intervention
Participants were no better than chance at identifying which
treatment they had received and this did not differ between
groups (numbers saying ‘active’ and ‘placebo’ respectively,
were thirty-eight and fifty-eight for the EPA þ DHA group
and thirty-one and sixty-three for the placebo group;
P¼0·34 from a x2 test). Twelve participants said that they
had received cod liver oil, fish oil or n-3 oils, of which ten
were in the EPA þ DHA group. Other guesses at what the
capsules contained included vitamins (thirty-nine), minerals
(seven), oils (five) and herbal extracts (three).
Discussion
The main finding of the present trial is the lack of a therapeuti-
cally important effect of n-3 LCPUFA supplementation on
depressed mood among people with mild to moderate
depression. The confidence interval for the primary outcome
(DASS depression score) excluded both a therapeutically ben-
eficial effect and a harmful effect. Similarly, other measures of
depressed mood were not improved by EPA þ DHA over pla-
cebo. Indeed, all measured aspects of mood and mental health,
including anxiety, stress and cognitive function, were unaf-
fected by supplementation, even in the subgroup with a
higher level of depression on entry into the trial. For this sub-
group, which at baseline scored in the range of moderate to
severe depression on the DASS, there was not even a slight
trend toward a benefit of EPA þ DHA supplementation.
To the authors’ knowledge, this is the largest trial investi-
gating the effects of n-3 LCPUFA supplementation on
depressed mood to be completed to date. Great care was
taken to conceal the specific nature of the intervention and
blinding was successful. The EPA þ DHA supplement was
well tolerated and the loss to follow-up of 13% was lower
than anticipated for a non-clinical group participating in a
lengthy protocol. It is unlikely that the absence of beneficial
effects can be explained by the level or duration of supplemen-
tation. Compliance appeared to be good and after 12 weeks
plasma EPA þ DHA concentration in the supplemented group
was twice that of the placebo group. A similar effect on blood
concentrations of EPA þ DHA was reported recently in a
trial using a higher level of EPA þ DHA supplementation for
12 weeks42. Even with much poorer compliance, supplemen-
tation would have increased n-3 LCPUFA intake to above
levels consistent with UK dietary recommendations. Recent
UK recommendations are for adults to consume at least two por-
tions of fish per week, one of which should be oily (equivalent to
about 3 g EPA þ DHA per week)2. Current intakes, especially
of oily fish, are considerably lower than this2.
The duration of supplementation in this trial was in line
with previous work in mental health. Three studies of n-3
LCPUFA found benefits for depressed mood of supplemen-
tation for 12 weeks or less43–45. Furthermore, in people with
bipolar disorder, changes in T2 whole brain relaxation times,
indicative of changes in neuronal membrane fluidity, have
been found after 4 weeks EPA þ DHA supplementation46.
Evidence from this study, however, was somewhat less clear
for the lowest dose investigated (2 g) and there did not
appear to be an effect on depression.
At baseline in the present trial, there was attentional avoid-
ance of the threat words (e.g. injury, violence, failure, criti-
cised) presented in the visual probe task. This avoidance
was more marked in the more depressed group. While atten-
tional vigilance for threat-related stimuli is commonly found
among those with generalised anxiety disorder, results for
depression are less clear, with relatively few previous reports
of visual probe tasks revealing attentional biases in
depression34. Similar to the results for the self-report measures
of depressed mood (DASS depression and BDI), attentional
avoidance of threat words declined over the 12 weeks of the
trial and again there was no effect of supplementation, even
for the more depressed group. In view of the interest in poss-
ible effects of n-3 LCPUFA in the treatment of ‘impulsivity
disorders’6, it is noteworthy that EPA þ DHA v. placebo
brought about a marginal improvement in performance on
the impulsivity task. However, this result must be treated
with considerable caution, as the number of secondary out-
comes examined in the analyses means there is a correspond-
ingly high probability of a Type I error (that is, observing a
difference by chance). Furthermore, even if it is confirmed,
the extent to which such an effect might predict a benefit
for impulsive behaviour generally or in relation to Attention
Deficit Hyperactivity Disorder, aggression or even suicide
risk4 is far from certain.
The evidence from this trial therefore does not favour a ben-
efit for depressed mood or cognitive function of increased n-3
LCPUFA intake. An association between dietary intake of n-3
LCPUFA and depressed mood has been found in various popu-
lations16,17; however, analysis of cross-sectional data on nearly
3000 of the people screened during recruitment for the present
trial did not confirm such a relationship when level of social and
economic deprivation and age were taken into account18. Fur-
thermore, depressed mood among the participants entering the
trial was not related to plasma n-3 LCPUFA concentrations.
Adding the present trial to a meta-analysis of the other random-
ised controlled trials on this subject21 confirms an overall
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negligible effect size for n-3 LCPUFA supplementation v. pla-
cebo (Fig. 4). This meta-analysis also reveals evidence of
heterogeneity and substantial funnel plot asymmetry, probably
due to publication bias and/or differences in trial populations21.
The participants for the present trial were recruited from
community-based settings and in general had mild to moderate
depressive symptoms. Those previous studies that have shown
benefits had much smaller sample sizes and enrolled individ-
uals with more severe depressive symptoms from clinical set-
tings. It remains that the present randomised trial is the largest
and most relevant to the general population. It did not provide
any evidence to support the use of n-3 LCPUFA to improve
depressed mood.
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